Autopsy report · NCT00655824

Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403

“The clinical development of intravenously administered ofatumumab in RA will no longer be pursued, so this study was prematurely terminated by the Sponsor.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months after it had already started.
• Ran for about 5 years 3 months before it stopped.
• 124 participants enrolled.
• Results were posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

GlaxoSmithKline

Sponsor type

Industry

Conditions

Arthritis, Rheumatoid

Interventions

ofatumumab

Participants

124

Sites

10

Countries

Denmark, Hungary, Poland, United Kingdom, United States

Trials that died the same way

• A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
  “Trial was terminated for business reasons. There has been no change in the benefit/risk profile of ofatumumab.” (75% match in meaning)
• Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate
  “The biological effect seen with natalizumab was not sufficient to warrant further development in RA.” (65% match in meaning)
• Study on Tolerability and Pharmacokinetics of TQB2858 Injection in Subjects With Advanced Malignant Tumors
  “The sponsor has decided to terminate this study based on the current clinical research status of dual antibody drugs and full communication with the investigators.” (64% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (62% match in meaning)
• A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia
  “The study was terminated due to lack of efficacy at any of the tested doses on 18th November 2022. The decision to terminate the study is not related to a safety concern.” (61% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.